1. Home
  2. DLNG vs SGMT Comparison

DLNG vs SGMT Comparison

Compare DLNG & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$4.00

Market Cap

155.0M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.48

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLNG
SGMT
Founded
2013
2006
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
155.0M
169.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DLNG
SGMT
Price
$4.00
$6.48
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.38
AVG Volume (30 Days)
100.1K
396.0K
Earning Date
05-26-2026
05-07-2026
Dividend Yield
5.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.10
N/A
P/E Ratio
$3.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.23
$2.36
52 Week High
$4.45
$11.41

Technical Indicators

Market Signals
Indicator
DLNG
SGMT
Relative Strength Index (RSI) 44.70 66.99
Support Level $3.77 $6.30
Resistance Level $4.25 $6.72
Average True Range (ATR) 0.14 0.35
MACD -0.03 0.16
Stochastic Oscillator 21.78 90.69

Price Performance

Historical Comparison
DLNG
SGMT

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: